{
    "2018-03-20": [
        [
            {
                "time": "",
                "original_text": "这个板块本轮反弹堪比“独角兽”！价投大旗能否由它扛起？（附股）",
                "features": {
                    "keywords": [
                        "板块",
                        "反弹",
                        "独角兽",
                        "价投"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "综合"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "[推荐评级]医药行业周报：医疗部门体系调整 关注医药流通板块",
                "features": {
                    "keywords": [
                        "医药",
                        "医疗部门",
                        "体系调整",
                        "医药流通"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "[买入评级]智飞生物(300122)年报点评：17年业绩高增长 18年HPV疫苗将迎来销售大年",
                "features": {
                    "keywords": [
                        "智飞生物",
                        "年报",
                        "业绩高增长",
                        "HPV疫苗",
                        "销售大年"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "[买入评级]智飞生物(300122)年报点评：三联苗快速放量 HPV疫苗值得期待",
                "features": {
                    "keywords": [
                        "智飞生物",
                        "年报",
                        "三联苗",
                        "HPV疫苗"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "[推荐评级]医药行业周报：国务院机构改革提升监管效率 医药行业长期趋势向好",
                "features": {
                    "keywords": [
                        "医药",
                        "国务院",
                        "机构改革",
                        "监管效率",
                        "长期趋势向好"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "爱康国宾再遇资本敲门 张黎刚面临私有化抉择",
                "features": {
                    "keywords": [
                        "爱康国宾",
                        "资本",
                        "私有化"
                    ],
                    "sentiment_score": 0.4,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医疗健康"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}